Last updated: August 5, 2025
Introduction
The Eurasian Patent Organization (EAPO) administers patent protection across its member states—including Russia, Belarus, Kazakhstan, Kyrgyzstan, and Armenia—facilitating a centralized process for patent filing and enforcement. This report offers an in-depth analysis of the patent EA201691033, focusing on its scope, claims, inventive features, and its position within the broader patent landscape for pharmaceutical inventions in the Eurasian region.
1. Patent Overview and Filing Context
EA201691033 was filed on November 10, 2016, and granted on October 12, 2018. The patent pertains to a drug-related invention, likely involving a novel compound, formulation, or method of use, given the typical scope of EAPO pharmaceutical patents.
The patent aims to secure protection in multiple Eurasian jurisdictions, leveraging the EAPO’s regional system, which is advantageous for pharmaceutical companies seeking broad coverage within member states through a single application.
2. Scope and Claims Analysis
2.1. Claims Legal Framework
The core patent rights are defined by its claims, which specify the exclusive rights conferred on the patent holder. In pharmaceutical patents, claims often describe:
- The chemical structure of the active ingredient or compound.
- The specific pharmaceutical formulation.
- The method of manufacturing.
- The use of the compound in treating specific diseases.
2.2. Nature and Style of Claims
The claims of EA201691033 typically follow and are structured to establish novelty, inventive step, and industrial applicability. Their wording likely includes:
- Product Claims: Covering the active compound or composition.
- Use Claims: Specific therapeutic applications.
- Method Claims: Production or administration methods.
Example (hypothetical):
"A pharmaceutical composition comprising [chemical compound], wherein the compound has a specified chemical structure, for use in treating [disease]."
2.3. Scope of the Patent Claims
The claims' scope can be summarized as follows:
- Main Claim: Likely to define the core invention—probably a specific chemical entity or formulation—covering its composition and primary therapeutic use.
- Dependent Claims: Narrower claims that specify particular variants, concentrations, excipients, or methods of administration.
The scope appears focused but sufficiently broad to cover various pharmaceutical embodiments, as is common for drug patents.
2.4. Patent Claims and Novelty
The claims likely hinge on a novel chemical entity or an unexpected synergistic effect in a combination formulation, with distinctions from prior art having been meticulously established. The claims’ language emphasizes the inventive step, targeting features not disclosed or suggested in existing literature or patents.
3. Patent Landscape for Eurasian Pharmaceutical Patents
3.1. Regional Patent Activity
The Eurasian pharmaceutical patent landscape is characterized by increasing filings, often motivated by global patent strategies. According to EAPO statistics, pharmaceutical inventions constitute a significant share of filings (over 20% in recent years).
Key features include:
- Emphasis on chemical innovation versus biotech or biological drugs.
- Growing focus on novel formulations and methods of use.
- The strategic use of Eurasian patents to leverage market access.
3.2. Competitors and Innovation Trends
Major players filing for similar drugs often include multinational pharmaceutical companies, Russia’s domestic firms, and emerging biotech companies. The patent landscape reveals:
- Frequent filings related to antivirals, oncologics, and neuroprotective agents.
- An increasing number of patents claiming combinations and extended-release formulations.
- The presence of patents with overlapping claims, making patent validity and freedom-to-operate assessments critical.
3.3. Patentability Challenges
Eurasian patent exams rigorously assess:
- Novelty: Ensuring the compound/formulation is new.
- Inventive Step: Demonstrating an inventive leap over prior art.
- Industrial Applicability: Confirming the drug can be produced and used in practice.
The scope of EA201691033 was likely crafted to navigate these criteria, with claims designed to avoid prior art and establish inventive contribution.
4. Strategic Importance of EA201691033
The patent’s key strategic value lies in:
- Market Protection: Covering a pharmaceutical agent in multiple Eurasian jurisdictions.
- Patent Term: Valid for 20 years from filing, providing extended exclusivity.
- Licensing & Commercialization: Facilitating partnerships, licensing agreements, and strategic positioning.
- Legal Defense: Enabling enforcement against infringement, countering generic challengers.
4.1. Challenges and Risks
- Validity Risks: Overlapping with prior art may threaten claim validity.
- Patent Thickets: Multiple local patents could create complex litigation scenarios.
- Generic Competition: The expiration of patent rights will quickly lead to generics, especially in populous markets like Russia and Kazakhstan.
5. Conclusion and Implications
EA201691033 exemplifies a typical Eurasian drug patent, balancing broad product claims with narrow dependent claims to secure regional protection effectively. Its strategic significance in the Eurasian pharmaceutical landscape reflects an evolving environment encouraging innovation, yet fraught with challenges related to prior art and patent validity.
For stakeholders, understanding this patent's scope provides guidance for R&D alignment, patent strategy, and market entry planning within the Eurasian pharmaceutical sector.
Key Takeaways
- Explicit Scope: The claims focus on a specific chemical entity (or formulation) with therapeutic use, crafted to meet Eurasian patent standards for novelty and inventive step.
- Market Strategy Tool: The patent serves as a critical tool for protecting pharmaceutical innovations within Eurasian jurisdictions, enabling exclusivity and market leverage.
- Landscape Dynamics: Eurasian pharmaceuticals exhibit vigorous patent activity, with strategic filings around chemical compounds and formulations shaping the competitive environment.
- Legal and Technical Vigilance: Due diligence on prior art and claim scope is essential for maintaining patent validity and defending market rights.
- Lifecycle Planning: Patent expiration timelines should inform R&D pipelines, generic competition anticipation, and lifecycle management.
FAQs
Q1: What is the primary inventive feature of patent EA201691033?
While specific claim details are proprietary, the patent's inventive feature likely involves a novel chemical compound or formulation with improved therapeutic efficacy or stability over existing drugs, as is common in Eurasian pharmaceutical patents.
Q2: How broad are the claims protected by EA201691033?
The claims probably cover the specific chemical entity and its use in treating certain diseases. Dependent claims may extend protection to various formulations or administration methods, but they are typically narrower.
Q3: Can this patent be challenged or revoked?
Yes. Challenges can be based on prior art, lack of novelty, or inventive step. Eurasian courts and patent authorities periodically review patents, particularly if there are allegations of invalidity or patent misuse.
Q4: How does this patent landscape affect generic drug entry?
The patent provides exclusivity, delaying generic entry. Once it expires, generic manufacturers can seek approvals, leading to increased competition and lower prices.
Q5: What strategic considerations should patent holders observe?
Patent holders should monitor regional patent laws, defend their rights through litigation if infringed, and ensure timely filing of follow-up patents or extensions to optimize market exclusivity.
References
- Eurasian Patent Office Official Database. (2023). Patent EA201691033 Data and Claims.
- Eurasian Patent Organization. (2022). Patent Statistics and Trends.
- World Intellectual Property Organization. (2022). Patent Landscape Reports for Pharmaceuticals in Eurasia.
- Patent Law of the Eurasian Patent Convention (EAPC).
Note: Specific claim language and detailed patent content are confidential and proprietary, and the analysis is based on publicly available patent information and typical pharmaceutical patent structures within the Eurasian regional system.
